The iBioLaunch™ platform is a  proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins.  The plants are easily and reliably scaled-up in low cost, controlled growth facilities to produce large amounts of recombinant protein in the plant biomass.  The technology is highly flexible having the capability to produce both biotherapeutics and vaccines. Advantages of the whole plant approach include lower operating and capital expenses compared to protein production using engineered microbial or animal cells in bioreactors. The iBioLaunch platform offers significant advantages over earlier plant-based methods that rely on transgenic plants or plant cell cultures. These include the speed at which different proteins can be expressed and produced at commercial scale, which presents a significant commercial advantage, as well as public safety benefits when vaccines for pandemic diseases are required.  Other advantages include scalability, no risks of contamination by animal pathogens, and the ability to express complex proteins at which other systems have failed.


The iBioLaunch technology platform addresses several multi-billion dollar markets.  Its applicability to a broad range of product classes enables iBio to target global commercial collaborations in high-growth markets such as orphan biologics ($54.6 billion in 2009), biosimilars/bio-betters (~$80 billion worth of biologics sales will be susceptible to biosimilar competition, by 2013) and new proprietary biologics. The speed and superior economic scalability of the iBioLaunch™ technology make it the ideal platform for new personalized therapeutics as well as for vaccines ($32 billion in 2013).